Adlai Nortye Ltd. (ANL)

Biotechnology · market cap $1.0B · as of 2026-07-07

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology company with 123 employees and a market cap of approximately $435M at ~$9.49/share. Its lead and sole disclosed pipeline asset is the combination of buparlisib and paclitaxel in a Phase 3 trial for head and neck cancer. No upcoming catalysts are currently scheduled on the public calendar, and key financial details including cash position, runway, and dilution history are not disclosed in available data.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Buparlisib & Paclitaxel	Phase 3	Head and Neck Cancer

Price & technical context

3-month

+44.0%

6-month

+126.5%

12-month

+836.7%

52-wk range

$0.88–$16.60

vs 50-day MA

+14.9%

vs 200-day MA

+60.9%

Realized vol

130.7%

Max drawdown

-75.1%

Daily closes through 2026-09-24. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for ANL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.